Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fasudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 8/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 7/20 | 0.98 |
| ▸ | CCR2 | P41597 | 2/20 | 0.98 |
| ▸ | HTT | P42858 | 2/20 | 0.98 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.95 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.95 |
| ▸ | PRKD1 | Q15139 | 6/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.95 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.95 |
| ▸ | PRKCG | P05129 | 5/20 | 0.95 |
| ▸ | PRKCB | P05771 | 5/20 | 0.95 |
| ▸ | PRKCA | P17252 | 5/20 | 0.95 |
| ▸ | PRKCH | P24723 | 5/20 | 0.95 |
| ▸ | PRKCI | P41743 | 5/20 | 0.95 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.95 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.95 |
| ▸ | PRKACA | P17612 | 4/20 | 0.95 |
| ▸ | PRKACG | P22612 | 4/20 | 0.95 |
| ▸ | PRKACB | P22694 | 4/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fasudil SCHEMBL4725334 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6269513 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL2154690 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL4728659 | 1.00 | ROCK2 (0.98) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL317082 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL6032335 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL599053 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29393852 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL30084458 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE | |
| Fasudil SCHEMBL29351490 | 0.99 | ROCK2 (1.00) | ROCK2ROCK1CCR2HTTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551223-A1 | ORAL LIPOSOMAL FORMULATIONS OF FASUDIL | Woolsey Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4479058-A1 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | Woolsey Pharmaceuticals, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4479035-A1 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | Woolsey Pharmaceuticals, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118871102-A | Taste masking oral preparation of fasudil | 悟而喜制药公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4440566-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | Woolsey Pharmaceuticals, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4429667-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS AND DOSING REGIMEN FOR SAME | Woolsey Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118369099-A | Methods for treating amyotrophic lateral sclerosis | 悟而喜制药公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118354769-A | Methods for treating behavioral symptoms associated with shock and other dementias | 悟而喜制药公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118251226-A | Methods of treating amyotrophic lateral sclerosis and dosing regimens therefor | 悟而喜制药公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024011120-A1 | ORAL LIPOSOMAL FORMULATIONS OF FASUDIL | WOOLSEY PHARMACEUTICALS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023158789-A1 | ORAL FORMULATIONS OF FASUDIL WITH ION EXCHANGE RESIN | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158787-A1 | TASTE-MASKING ORAL FORMULATIONS OF FASUDIL | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| CN-116249532-A | Methods of treating vascular dementia using Rho kinase inhibitors | 乌尔塞制药公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023097151-A1 | METHODS OF TREATING AGITATION AND OTHER DEMENTIA-ASSOCIATED BEHAVIORAL SYMPTOMS | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023086468-A1 | METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS AND DOSING REGIMEN FOR SAME | WOOLSEY PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4171564-A1 | METHODS OF TREATING NEURODEVELOPMENTAL DISORDERS | Woolsey Pharmaceuticals, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996728-A | Methods of treating Alzheimer's disease using Rho kinase inhibitors | 乌尔塞制药公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4164652-A1 | METHODS OF USING RHO KINASE INHIBITORS TO TREAT VASCULAR DEMENTIA | Woolsey Pharmaceuticals, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115916187-A | Methods of treating proteinopathic-related wandering | 乌尔塞制药公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4087564-A1 | METHODS OF TREATING CORTICAL DEMENTIA ASSOCIATED WANDERING | Woolsey Pharmaceuticals, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |